Immunic
Update in progressIMUX (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Immunic, Inc. is a biotechnology company focused on selective oral immunology therapies for chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead program, IMU-838, is in Phase 3 for relapsing and progressive multiple sclerosis and Phase 2 for moderate-to-severe ulcerative colitis. IMU-856 is in Phase 2 to restore intestinal barrier function in GI diseases; IMU-381 is preclinical for GI diseases. Founded 2016, based in New York.
Company score
- Sentiment
- 0.45
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.23
- Governance
- 0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.27
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!